Cargando…

Female sexual function in bladder cancer: A review of the evidence

BACKGROUND: Bladder cancer (BC) treatments are known to be invasive; nevertheless, research into the long‐term effects is limited and in the context of sexual function often male focussed. Female sexual dysfunction (FSD) has been reported in up to 75% of female patients. This systematic scoping revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Rebecca, Renouf, Tessa, Rigby, Jeannie, Hafeez, Shaista, Thurairaja, Ramesh, Kumar, Pardeep, Cruickshank, Susanne, Van‐Hemelrijck, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766865/
https://www.ncbi.nlm.nih.gov/pubmed/36569507
http://dx.doi.org/10.1002/bco2.186
_version_ 1784853834354393088
author Martin, Rebecca
Renouf, Tessa
Rigby, Jeannie
Hafeez, Shaista
Thurairaja, Ramesh
Kumar, Pardeep
Cruickshank, Susanne
Van‐Hemelrijck, Mieke
author_facet Martin, Rebecca
Renouf, Tessa
Rigby, Jeannie
Hafeez, Shaista
Thurairaja, Ramesh
Kumar, Pardeep
Cruickshank, Susanne
Van‐Hemelrijck, Mieke
author_sort Martin, Rebecca
collection PubMed
description BACKGROUND: Bladder cancer (BC) treatments are known to be invasive; nevertheless, research into the long‐term effects is limited and in the context of sexual function often male focussed. Female sexual dysfunction (FSD) has been reported in up to 75% of female patients. This systematic scoping review examines the literature on sexual consequences of BC in female patients. OBJECTIVE: This study aimed to systematically evaluate the evidence on female sexual function in BC to identify areas of unmet need and research priorities. EVIDENCE ACQUISITION: We performed a critical review of PubMed, PsychMed, CINAHL, MEDLINE and the Cochrane Library in March 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) extension for Scoping Reviews statement following Levac et al. methodology. Identified reports were reviewed according to the Critical Appraisal Skills Programme (CASP) criteria. 45 publications were included. EVIDENCE SYNTHESIS: There was an inconsistent use of patient‐reported outcome measures (PROMs), with commonly used PROMs having a narrow symptom focus. However, common symptoms emerged: loss of desire, orgasmic disorders, vaginal dryness, dyspareunia, difficult intromission, reduced clitoral sensation, psychological concerns related to diagnosis, fear of contamination and body image. Sexual activity was reduced in most groups, despite women expressing a motivation to retain sexual function. The degree of symptom distress associated with FSD is underreported. Evidence emerged regarding a gap for women in clinician counselling and follow‐up. CONCLUSIONS: The patient's perspective of FSD in BC patients is poorly understood and under‐addressed in clinical practice. There have been very few qualitative studies of FSD in BC. Any intervention designed to address the problem must start with greater understanding of both the patients' and clinicians' perspective. LAY SUMMARY: We examined the evidence on sexual consequences of BC in women. It is apparent that despite common themes of sexual dysfunction emerging, the problem is poorly understood and addressed in clinical practice.
format Online
Article
Text
id pubmed-9766865
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97668652022-12-23 Female sexual function in bladder cancer: A review of the evidence Martin, Rebecca Renouf, Tessa Rigby, Jeannie Hafeez, Shaista Thurairaja, Ramesh Kumar, Pardeep Cruickshank, Susanne Van‐Hemelrijck, Mieke BJUI Compass Reviews BACKGROUND: Bladder cancer (BC) treatments are known to be invasive; nevertheless, research into the long‐term effects is limited and in the context of sexual function often male focussed. Female sexual dysfunction (FSD) has been reported in up to 75% of female patients. This systematic scoping review examines the literature on sexual consequences of BC in female patients. OBJECTIVE: This study aimed to systematically evaluate the evidence on female sexual function in BC to identify areas of unmet need and research priorities. EVIDENCE ACQUISITION: We performed a critical review of PubMed, PsychMed, CINAHL, MEDLINE and the Cochrane Library in March 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) extension for Scoping Reviews statement following Levac et al. methodology. Identified reports were reviewed according to the Critical Appraisal Skills Programme (CASP) criteria. 45 publications were included. EVIDENCE SYNTHESIS: There was an inconsistent use of patient‐reported outcome measures (PROMs), with commonly used PROMs having a narrow symptom focus. However, common symptoms emerged: loss of desire, orgasmic disorders, vaginal dryness, dyspareunia, difficult intromission, reduced clitoral sensation, psychological concerns related to diagnosis, fear of contamination and body image. Sexual activity was reduced in most groups, despite women expressing a motivation to retain sexual function. The degree of symptom distress associated with FSD is underreported. Evidence emerged regarding a gap for women in clinician counselling and follow‐up. CONCLUSIONS: The patient's perspective of FSD in BC patients is poorly understood and under‐addressed in clinical practice. There have been very few qualitative studies of FSD in BC. Any intervention designed to address the problem must start with greater understanding of both the patients' and clinicians' perspective. LAY SUMMARY: We examined the evidence on sexual consequences of BC in women. It is apparent that despite common themes of sexual dysfunction emerging, the problem is poorly understood and addressed in clinical practice. John Wiley and Sons Inc. 2022-09-24 /pmc/articles/PMC9766865/ /pubmed/36569507 http://dx.doi.org/10.1002/bco2.186 Text en © 2022 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Martin, Rebecca
Renouf, Tessa
Rigby, Jeannie
Hafeez, Shaista
Thurairaja, Ramesh
Kumar, Pardeep
Cruickshank, Susanne
Van‐Hemelrijck, Mieke
Female sexual function in bladder cancer: A review of the evidence
title Female sexual function in bladder cancer: A review of the evidence
title_full Female sexual function in bladder cancer: A review of the evidence
title_fullStr Female sexual function in bladder cancer: A review of the evidence
title_full_unstemmed Female sexual function in bladder cancer: A review of the evidence
title_short Female sexual function in bladder cancer: A review of the evidence
title_sort female sexual function in bladder cancer: a review of the evidence
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766865/
https://www.ncbi.nlm.nih.gov/pubmed/36569507
http://dx.doi.org/10.1002/bco2.186
work_keys_str_mv AT martinrebecca femalesexualfunctioninbladdercancerareviewoftheevidence
AT renouftessa femalesexualfunctioninbladdercancerareviewoftheevidence
AT rigbyjeannie femalesexualfunctioninbladdercancerareviewoftheevidence
AT hafeezshaista femalesexualfunctioninbladdercancerareviewoftheevidence
AT thurairajaramesh femalesexualfunctioninbladdercancerareviewoftheevidence
AT kumarpardeep femalesexualfunctioninbladdercancerareviewoftheevidence
AT cruickshanksusanne femalesexualfunctioninbladdercancerareviewoftheevidence
AT vanhemelrijckmieke femalesexualfunctioninbladdercancerareviewoftheevidence